CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from Chardan Capital analyst Geulah Livshits ...

JP Morgan has recently reduced Editas Medicine Inc (EDIT) stock to Underweight rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 13, 2024, Truist had reduced the ...

Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $1.38 which represents a decrease of $-0.03 or -2.13% from the prior close of $1.41. The stock opened at $1.41 and touched a low of $1 ...

Equities research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Editas Medicine in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs ...

Analysts at Zacks Research decreased their FY2024 earnings per share (EPS) estimates for Editas Medicine in a report issued on Tuesday, January 21st. Zacks Research analyst A. Chakraborty now expects ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu from Wells Fargo maintained a Hold rating on the ...

CAMBRIDGE, Mass. – Editas Medicine , Inc. (NASDAQ:EDIT), a leader in gene editing technology currently valued at $104 million in market capitalization, has unveiled significant advancements in its in ...

Editas Medicine reports preclinical success in gene editing for sickle cell disease and beta thalassemia, with strategic milestones for 2025. Editas Medicine, Inc. announced significant ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced its ...

CAMBRIDGE, Mass. – Editas Medicine , Inc. (NASDAQ:EDIT), a leader in gene editing technology currently valued at $104 million in market capitalization, has unveiled significant advancements in ...